8-K: Intensity Therapeutics Gains Nasdaq Bid Price Extension

Intensity Therapeutics, Inc. received a 180-day extension until June 1, 2026, to regain compliance with Nasdaq's minimum $1.00 bid price requirement, avoiding immediate delisting.

Summary

• Intensity Therapeutics, Inc. (INTS) received a letter from Nasdaq on December 4, 2025, granting an additional 180 calendar days to regain compliance with the minimum $1.00 bid price requirement (Nasdaq Listing Rule 5550(a)(2)).
• The new compliance deadline is June 1, 2026.
• This extension follows the expiration of the initial 180-day compliance period on December 3, 2025, which began on June 6, 2025.
• To regain compliance, the company's common stock must maintain a closing bid price of at least $1.00 per share for a minimum of ten consecutive business days.
• The company intends to actively monitor its stock price and will consider options, including a reverse stock split, if necessary, to meet the requirement.
• Failure to comply by June 1, 2026, could lead to delisting, though the company would have the right to appeal to a Hearings Panel.
• The notification has no immediate effect on the listing or trading of the company's common stock on the Nasdaq Capital Market.

Sentiment

Score: 4

Explanation: The extension provides a temporary reprieve from immediate delisting, which is a positive. However, the underlying issue of non-compliance with the minimum bid price requirement persists, and the potential need for a reverse stock split indicates ongoing challenges for the company's stock performance. The situation is neutral to slightly negative as it highlights continued weakness in stock price.

Positives

• Granted a 180-day extension until June 1, 2026, to regain compliance with Nasdaq's minimum bid price requirement.
• No immediate effect on the company's continued listing or trading on the Nasdaq Capital Market.
• The company has a stated intention to cure the deficiency, including considering a reverse stock split if needed.

Negatives

• The company remains non-compliant with Nasdaq's minimum $1.00 bid price requirement.
• Potential need for a reverse stock split, which can sometimes be viewed negatively by investors.
• Risk of delisting from Nasdaq if compliance is not achieved by June 1, 2026.
• An indicator of non-compliance will continue to be broadcast over Nasdaq's market data network, and the company will remain on Nasdaq's list of non-compliant companies.

Risks

• Failure to maintain a minimum closing bid price of $1.00 per share could lead to the delisting of the company's common stock from the Nasdaq Capital Market.
• The company may need to effect a reverse stock split, which could impact shareholder perception and liquidity.
• General risks and uncertainties described in the Risk Factors sections of the company's Annual Report on Form 10-K and Quarterly Reports on Form 10-Q.

Future Outlook

The company intends to actively monitor the closing bid price of its common stock and will consider all available options, including a reverse stock split if necessary, to regain compliance with Nasdaq's minimum bid price requirement by June 1, 2026.

Management Comments

• "The Company intends to actively monitor the closing bid price of its common stock and will consider available options to regain compliance with the Minimum Bid Price Requirement and the other Nasdaq listing requirements."
• "Such available options will include effecting a reverse stock split of the Company's common stock, if necessary, in order to maintain the Company's Nasdaq listing."

Industry Context

This announcement is specific to Intensity Therapeutics' compliance with Nasdaq listing rules and does not directly reflect broader industry trends. However, maintaining a Nasdaq listing is crucial for biotechnology companies like Intensity Therapeutics to access capital markets and maintain investor visibility, which is a common challenge for development-stage companies without significant revenue.

Stakeholder Impact

• Shareholders: Face continued uncertainty regarding the company's Nasdaq listing and potential dilution or value adjustment from a reverse stock split. The non-compliance indicator on Nasdaq's network may also affect investor confidence.
• Employees: No direct impact mentioned, but delisting could affect company stability and future capital access, indirectly impacting employees.
• Customers/Suppliers/Creditors: No direct impact mentioned in this filing.

Next Steps

• Actively monitor the closing bid price of common stock.
• Consider available options to regain compliance, including a reverse stock split if necessary.
• Achieve a closing bid price of at least $1.00 per share for a minimum of ten consecutive business days on or prior to June 1, 2026.
• If compliance is not met by June 1, 2026, the company may appeal a delisting determination to a Hearings Panel.

Key Dates

Recommendation

The extension provides a temporary relief from immediate delisting, which prevents a sharp negative reaction. However, the underlying issue of the stock trading below $1.00 persists, and the potential for a reverse stock split introduces uncertainty and can be a negative signal to the market. Investors should hold to see if the company can regain compliance organically or through a reverse split, but the situation does not present a strong buy signal due to the ongoing listing risk and weak stock performance. A "hold" allows for observation of the company's actions and market reaction to the compliance efforts.

Keywords

Intensity Therapeutics, INTS, Nasdaq, Listing Compliance, Minimum Bid Price, Reverse Stock Split, Delisting Risk, Biotechnology, Cancer Therapies, INT230-6